Avia D. Wilkerson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Avia D. Wilkerson has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Alberto J. Montero
Case Western Reserve University
20 shared publications - C. Marcela Diaz-Montero
Cleveland Clinic 7 Cleveland, OH
20 shared publications - Patricia A. Rayman
Cleveland Clinic Foundation, Center for Immunotherapy & Precision Immuno-Oncology, Lerner Research Institute, Cleveland, USA
20 shared publications - Paul G. Pavicic
Cleveland Clinic 8 Cleveland, Ohio
20 shared publications - Timothy A. Chan
Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA
20 shared publications - Tyler J. Alban
Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, USA
20 shared publications
Latest Publications
- Open Access
- 17 May 2025
- Published by Springer Nature in Communications Medicine
- Vol. 5 (1) , 1-12
Responses to checkpoint inhibition in metastatic triple negative breast cancer driven by divergent myeloid phenotypes
Background Given the scarcity of effective therapeutic targets, metastatic triple negative breast cancer (mTNBC) has shorter survival times compared to other advanced breast cancer subtypes. Although chemo-immunotherapy with immune checkpoint inhibitors (ICIs) in PD-L1+ mTNBC has shown promise, survival benefit remains modest. Therefore, it is crucial to gain improved insight into the mechanisms underlying response and resistance to checkpoint inhibition in mTNBC. Methods We employed single cell RNA sequencing (scRNAseq), single cell secretomics, and flow cytometry to identify transcriptomic and proteomic peripheral immune cell signatures associated with response and non-response to anti-PD-1/PD-L1 therapy and chemotherapy in mTNBC. Results Transcriptomic analysis reveal divergent transcriptional programming of CD33+ myeloid cells between responders and non-responders, even in pretreatment PBMC samples. This divergence, in responders, is characterized by an immune-promoting CD33+ cell phenotype involving IL1b signaling compared to non-responders, where an immunosuppressive phenotype marked by IL1b inhibition is observed. These baseline differences become more pronounced during the course of chemo-immunotherapy. Differences in CD33+ cell phenotype result in functional differences in lymphocyte activities between responders and non-responders. Depletion of CD33+ cells in pre-treatment samples from non-responders, restores T cell effector function. Conclusion Our findings highlight CD33+ cell phenotype as a key determinant of response to chemo-immunotherapy, which can be assessed from peripheral blood. This offers a valuable tool in the context of metastatic TNBC, in which tissue sampling is often challenging.
- 17 May 2025
- Published by Springer Nature in Communications Medicine
- Vol. 5 (1) , 1-12
Open AccessResponses to checkpoint inhibition in metastatic triple negative breast cancer driven by divergent myeloid phenotypes
Background Given the scarcity of effective therapeutic targets, metastatic triple negative breast cancer (mTNBC) has shorter survival times compared to other advanced breast cancer subtypes. Although chemo-immunotherapy with immune checkpoint inhibitors (ICIs) in PD-L1+ mTNBC has shown promise, survival benefit remains modest. Therefore, it is crucial to gain improved insight into the mechanisms underlying response and resistance to checkpoint inhibition in mTNBC. Methods We employed single cell RNA sequencing (scRNAseq), single cell secretomics, and flow cytometry to identify transcriptomic and proteomic peripheral immune cell signatures associated with response and non-response to anti-PD-1/PD-L1 therapy and chemotherapy in mTNBC. Results Transcriptomic analysis reveal divergent transcriptional programming of CD33+ myeloid cells between responders and non-responders, even in pretreatment PBMC samples. This divergence, in responders, is characterized by an immune-promoting CD33+ cell phenotype involving IL1b signaling compared to non-responders, where an immunosuppressive phenotype marked by IL1b inhibition is observed. These baseline differences become more pronounced during the course of chemo-immunotherapy. Differences in CD33+ cell phenotype result in functional differences in lymphocyte activities between responders and non-responders. Depletion of CD33+ cells in pre-treatment samples from non-responders, restores T cell effector function. Conclusion Our findings highlight CD33+ cell phenotype as a key determinant of response to chemo-immunotherapy, which can be assessed from peripheral blood. This offers a valuable tool in the context of metastatic TNBC, in which tissue sampling is often challenging.
- Open Access
- 25 April 2025
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 212 (1) , 87-95
First mammogram-detected cancers portend worse survival in young women diagnosed with breast cancer
Purpose: Breast cancer (BC) screening guidelines for women ages 40–45 have differed across multiple organizations, resulting in variable ages of screening commencement among women in the US. We previously reported that delay in screening beyond age 40 increases risk for first mammogram cancer diagnoses. We hypothesize that first mammogram cancer detection may also diminish recurrence-free and overall survival (RFS, OS). Study design: This retrospective cohort study included 738 women diagnosed with BC from ages 40–45 years and treated within a single hospital system from 2010 to 2019. First mammogram cancers were defined as those with tissue diagnoses established within 3 months of baseline mammogram. RFS after surgery and OS after BC diagnosis were analyzed in patients diagnosed on first versus subsequent mammograms via the Kaplan–Meier method, with p-values generated by log rank tests. Cumulative incidences of local and distant recurrence were also assessed. Results: Of 738 women, 218 had first mammogram cancers while 520 were diagnosed on subsequent mammograms. Median follow-up was 72.2 months (0.5–155.8 months). At 5 and 10 years after diagnosis, OS was significantly worse in patients diagnosed on their first mammogram (0.88 [0.83–0.93] and 0.80 [0.73–0.87]) versus subsequent mammograms (0.95 [0.93–0.97] and 0.90 [0.86–0.93]), p = 0.003. Patients with first mammogram cancers also had inferior 5– and 10–years RFS rates (0.81 [0.71–0.88] and 0.74 [0.65–0.83] vs. 0.88 [0.85–0.92] and 0.77 [0.72–0.83]), p = 0.04. Conclusion: First mammogram cancers were associated with worse survival in our study cohort, reinforcing the importance of consistent guidelines for screening commencement at age 40.
- 25 April 2025
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 212 (1) , 87-95
Open AccessFirst mammogram-detected cancers portend worse survival in young women diagnosed with breast cancer
Purpose: Breast cancer (BC) screening guidelines for women ages 40–45 have differed across multiple organizations, resulting in variable ages of screening commencement among women in the US. We previously reported that delay in screening beyond age 40 increases risk for first mammogram cancer diagnoses. We hypothesize that first mammogram cancer detection may also diminish recurrence-free and overall survival (RFS, OS). Study design: This retrospective cohort study included 738 women diagnosed with BC from ages 40–45 years and treated within a single hospital system from 2010 to 2019. First mammogram cancers were defined as those with tissue diagnoses established within 3 months of baseline mammogram. RFS after surgery and OS after BC diagnosis were analyzed in patients diagnosed on first versus subsequent mammograms via the Kaplan–Meier method, with p-values generated by log rank tests. Cumulative incidences of local and distant recurrence were also assessed. Results: Of 738 women, 218 had first mammogram cancers while 520 were diagnosed on subsequent mammograms. Median follow-up was 72.2 months (0.5–155.8 months). At 5 and 10 years after diagnosis, OS was significantly worse in patients diagnosed on their first mammogram (0.88 [0.83–0.93] and 0.80 [0.73–0.87]) versus subsequent mammograms (0.95 [0.93–0.97] and 0.90 [0.86–0.93]), p = 0.003. Patients with first mammogram cancers also had inferior 5– and 10–years RFS rates (0.81 [0.71–0.88] and 0.74 [0.65–0.83] vs. 0.88 [0.85–0.92] and 0.77 [0.72–0.83]), p = 0.04. Conclusion: First mammogram cancers were associated with worse survival in our study cohort, reinforcing the importance of consistent guidelines for screening commencement at age 40.
- Open Access
- 21 August 2024
- Published by Springer Nature in Surgical Endoscopy
- Vol. 38 (11) , 6827-6838
Association between geospatial disparities in food security with weight loss and nutritional outcomes of metabolic surgery
Background: Food insecurity has been linked to higher rates of obesity. It has also been shown to diminish the effectiveness of weight loss strategies, including intensive lifestyle interventions. One essential component of food insecurity is having a geospatial disadvantage in access to healthy, affordable food, such as living within a food desert. This study aims to determine if food insecurity also impacts weight loss and nutritional outcomes in patients who underwent Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG). Methods: Clinical outcomes of patients who underwent RYGB or SG at Cleveland Clinic or affiliate regional hospitals in the United States from 2010 to 2018 were collected. Modified Retail Food Environmental Index (mRFEI) data was collected from the Center for Disease Control and merged with patient census tract data, allowing the patient cohort to be divided into those living in areas identified as food secure (mRFEI > 10%), food swamps (mRFEI = 1–10%), or food deserts (mRFEI = 0). Postoperative weight change was evaluated with quadratic growth mixture models and stratified by surgery type. Results: A total of 5097 patients were included in this study cohort, including 3424 patients who underwent RYGB and 1673 who underwent SG. The median duration of follow-up was 2.3 years (IQR 0.89–3.6 years). Food security status was not associated with postoperative weight change (RYGB p = 0.73, SG p = 0.60), weight loss nadir (RYGB p = 0.60, SG p = 0.79), or weight regain (RYGB p = 0.93, SG p = 0.85). Deficiencies in nutritional markers at 1–2 years after surgery were also not significantly different between food security groups. Conclusion: Despite the established relationship between food insecurity and obesity, food insecurity does not negatively impact weight loss or nutritional outcomes following RYGB or SG, demonstrating metabolic surgery as a powerful and equitable tool for treating obesity. Level of Evidence: IV.
- 21 August 2024
- Published by Springer Nature in Surgical Endoscopy
- Vol. 38 (11) , 6827-6838
Open AccessAssociation between geospatial disparities in food security with weight loss and nutritional outcomes of metabolic surgery
Background: Food insecurity has been linked to higher rates of obesity. It has also been shown to diminish the effectiveness of weight loss strategies, including intensive lifestyle interventions. One essential component of food insecurity is having a geospatial disadvantage in access to healthy, affordable food, such as living within a food desert. This study aims to determine if food insecurity also impacts weight loss and nutritional outcomes in patients who underwent Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG). Methods: Clinical outcomes of patients who underwent RYGB or SG at Cleveland Clinic or affiliate regional hospitals in the United States from 2010 to 2018 were collected. Modified Retail Food Environmental Index (mRFEI) data was collected from the Center for Disease Control and merged with patient census tract data, allowing the patient cohort to be divided into those living in areas identified as food secure (mRFEI > 10%), food swamps (mRFEI = 1–10%), or food deserts (mRFEI = 0). Postoperative weight change was evaluated with quadratic growth mixture models and stratified by surgery type. Results: A total of 5097 patients were included in this study cohort, including 3424 patients who underwent RYGB and 1673 who underwent SG. The median duration of follow-up was 2.3 years (IQR 0.89–3.6 years). Food security status was not associated with postoperative weight change (RYGB p = 0.73, SG p = 0.60), weight loss nadir (RYGB p = 0.60, SG p = 0.79), or weight regain (RYGB p = 0.93, SG p = 0.85). Deficiencies in nutritional markers at 1–2 years after surgery were also not significantly different between food security groups. Conclusion: Despite the established relationship between food insecurity and obesity, food insecurity does not negatively impact weight loss or nutritional outcomes following RYGB or SG, demonstrating metabolic surgery as a powerful and equitable tool for treating obesity. Level of Evidence: IV.
- Open Access
- 12 February 2024
- Published by MDPI AG in Healthcare
- Vol. 12 (4) , 462
Disparities in Breast Cancer Care—How Factors Related to Prevention, Diagnosis, and Treatment Drive Inequity
Breast cancer survival has increased significantly over the last few decades due to more effective strategies for prevention and risk modification, advancements in imaging detection, screening, and multimodal treatment algorithms. However, many have observed disparities in benefits derived from such improvements across populations and demographic groups. This review summarizes published works that contextualize modern disparities in breast cancer prevention, diagnosis, and treatment and presents potential strategies for reducing disparities. We conducted searches for studies that directly investigated and/or reported disparities in breast cancer prevention, detection, or treatment. Demographic factors, social determinants of health, and inequitable healthcare delivery may impede the ability of individuals and communities to employ risk-mitigating behaviors and prevention strategies. The disparate access to quality screening and timely diagnosis experienced by various groups poses significant hurdles to optimal care and survival. Finally, barriers to access and inequitable healthcare delivery patterns reinforce inequitable application of standards of care. Cumulatively, these disparities underlie notable differences in the incidence, severity, and survival of breast cancers. Efforts toward mitigation will require collaborative approaches and partnerships between communities, governments, and healthcare organizations, which must be considered equal stakeholders in the fight for equity in breast cancer care and outcomes.
- 12 February 2024
- Published by MDPI AG in Healthcare
- Vol. 12 (4) , 462
Open AccessDisparities in Breast Cancer Care—How Factors Related to Prevention, Diagnosis, and Treatment Drive Inequity
Breast cancer survival has increased significantly over the last few decades due to more effective strategies for prevention and risk modification, advancements in imaging detection, screening, and multimodal treatment algorithms. However, many have observed disparities in benefits derived from such improvements across populations and demographic groups. This review summarizes published works that contextualize modern disparities in breast cancer prevention, diagnosis, and treatment and presents potential strategies for reducing disparities. We conducted searches for studies that directly investigated and/or reported disparities in breast cancer prevention, detection, or treatment. Demographic factors, social determinants of health, and inequitable healthcare delivery may impede the ability of individuals and communities to employ risk-mitigating behaviors and prevention strategies. The disparate access to quality screening and timely diagnosis experienced by various groups poses significant hurdles to optimal care and survival. Finally, barriers to access and inequitable healthcare delivery patterns reinforce inequitable application of standards of care. Cumulatively, these disparities underlie notable differences in the incidence, severity, and survival of breast cancers. Efforts toward mitigation will require collaborative approaches and partnerships between communities, governments, and healthcare organizations, which must be considered equal stakeholders in the fight for equity in breast cancer care and outcomes.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer
Representativeness of Study Participants
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer
Representativeness of Study Participants
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer
Selected Reactome Pathways for Figure 2A
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer
Selected Reactome Pathways for Figure 2A
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer
Pre-treatment core needle biopsy sites in patients with evaluated tumors
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer
Pre-treatment core needle biopsy sites in patients with evaluated tumors
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer
Selected Reactome Pathways for Figure 2A
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer
Selected Reactome Pathways for Figure 2A
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer
Differential IGHG1 expression between the IGHG1high (highest tertile) versus IGHG1low (lower tertiles) groups
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer
Differential IGHG1 expression between the IGHG1high (highest tertile) versus IGHG1low (lower tertiles) groups
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer
Heat map of Reactome Pathway Enrichment (Top 25, Bottom 25, and selected pathways) by pairwise comparison of radiographic response category (CR, PR, SD, PD)
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer
Heat map of Reactome Pathway Enrichment (Top 25, Bottom 25, and selected pathways) by pairwise comparison of radiographic response category (CR, PR, SD, PD)